「dr」の検索結果

Suggests initiating inpatient continuous glucose monitoring (CGM) for select hospitalized patients at high risk for hypoglycemia, combined with periodic point-of-care glucose checks for accuracy. Triggers include planning glucose monitoring for inpatients with prior severe hypoglycemia, renal or hepatic dysfunction, or age 65 years or older.

日本語の概要は準備中です。原文の説明を表示しています。

This skill guides clinicians to reassess glucose monitoring frequency when discontinuing continuous subcutaneous insulin infusion (CSII) or transitioning to multiple daily injections (MDI). It is triggered by phrases such as 'Plan for glucose monitoring after pump stop' or 'Determine SMBG/CGM frequency post-pump' to ensure individualized glycemic goals are met.

日本語の概要は準備中です。原文の説明を表示しています。

Reassesses annually the patient’s CGM sensor site health and care practices, including skin integrity, rotation, and hygiene. Triggered by phrases such as 'Yearly sensor site inspection' or 'Annual review of CGM insertion site rotation and hygiene'.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests continuous subcutaneous insulin infusion (CSII) for adults with type 1 diabetes mellitus who desire increased insulin delivery flexibility or improved treatment satisfaction and are capable of using the device. Clinical triggers include statements such as 'Patient wants more lifestyle flexibility with insulin' or 'Consider pump for improved satisfaction in T1DM'.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends continuing insulin pump therapy in hospitals with pump expertise; otherwise transitioning to scheduled subcutaneous basal bolus insulin if anticipated length of stay exceeds 1–2 days before pump discontinuation. Consider this when anticipating a hospital stay >2 days, lacking pump expertise, or needing to conserve supplies.

日本語の概要は準備中です。原文の説明を表示しています。

Reassesses annually the patient’s ability to use CGM trend information to adjust insulin doses. Triggered by yearly CGM skills check or annual review of trend-based dosing competence.

日本語の概要は準備中です。原文の説明を表示しています。

This skill screens for pregnancy intention in individuals with preexisting diabetes at every reproductive, diabetes, primary care, and urgent care/ER visit when clinically appropriate. Trigger phrases include reproductive planning, preconception care, or pregnancy intention discussion.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses the patient’s ability to troubleshoot insulin pump malfunctions such as occlusion, battery failure, or error messages. Trigger phrases include “Review pump alarm responses” and “Ensure patient knows steps for pump error”.

日本語の概要は準備中です。原文の説明を表示しています。

This skill reassesses the insulin plan when discontinuing continuous subcutaneous insulin infusion (CSII) and transitioning to multiple daily injections (MDI). It is triggered by phrases such as 'Review planned basal-bolus regimen after pump' and 'Confirm MDI dose calculations and schedule'.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends contraception when pregnancy is not desired for individuals with diabetes who could become pregnant. Triggered by discussions about pregnancy planning, contraception needs, or when pregnancy is not desired.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends postpartum endocrine care (diabetes management) in addition to usual obstetric care for individuals with preexisting diabetes (including those with pregnancy loss or termination). Triggered by postpartum care planning for patients with diabetes after delivery.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluates patient’s ability to use CGM trend information (arrows, rate of change) to make insulin dose adjustments. Triggers include reviewing patient’s response to CGM trends and checking if patient adjusts bolus based on glucose direction.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends real-time continuous glucose monitoring (RT-CGM) for adult patients with type 1 diabetes mellitus (T1DM) whose hemoglobin A1C is above individualized target. Consider when clinician notes 'T1DM A1C above goal, consider RT-CGM' or 'Patient willing to wear CGM daily, A1C elevated'.

日本語の概要は準備中です。原文の説明を表示しています。

Advises surgical referral for parathyroid carcinoma when feasible after achieving control of severe hypercalcemia. Triggered when a clinician confirms parathyroid carcinoma and inquires about curative options following medical stabilization of hypercalcemia.

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests administering a glucocorticoid antagonist (e.g., mifepristone) in patients with Cushing's disease who have diabetes or glucose intolerance and are not surgical candidates or have persistent disease after transsphenoidal surgery. Consider when encountering persistent hypercortisolism after TSS, contraindications to surgery, or comorbid diabetes/glucose intolerance requiring medical control.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests repeat transsphenoidal surgery for patients with persistent hypercortisolism after initial transsphenoidal surgery when imaging shows evidence of incomplete resection or a pituitary lesion. Clinical triggers include postoperative MRI revealing residual adenoma, persistent elevated UFC or late-night salivary cortisol, and visible pituitary lesion on imaging.

日本語の概要は準備中です。原文の説明を表示しています。

Classify the severity of hypercalcemia at the bedside — mild, moderate, or severe — by combining the corrected/ionized calcium level with the acuity and symptom pattern, and decide whether the patient needs urgent therapy. Trigger when a clinician asks "is this hypercalcemia severe", "how bad is this calcium level", "when to admit for hypercalcemia", "is this hypercalcemic crisis", "how to grade hypercalcemia", or shares a calcium level and asks how worried to be.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends obtaining an oncology consultation to direct treatment of the underlying malignancy causing hypercalcemia of malignancy. It is triggered when a clinician diagnoses HCM and seeks guidance on coordinating cancer‑directed therapy.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends measuring late-night salivary or serum cortisol to screen for Cushing's disease recurrence in patients with eucortisolism after transsphenoidal surgery, including cases where eucortisolism was established by medical treatment prior to surgery. Use when postoperative follow-up shows eucortisolism (normal morning cortisol/UFC) but concern for recurrence exists.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends using radiation therapy for corticotroph adenomas in Cushing's disease when imaging shows invasive features or mass‑effect concerns such as cavernous sinus invasion, suprasellar extension, or knobby protrusion. Consider RT when postoperative medical therapy has normalized cortisol but tumor progression or residual invasive disease is suspected.

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests radiation therapy or radiosurgery for adult patients with Cushing's disease who have failed transsphenoidal surgery (TSS) or have recurrent disease after initial remission. Consider when postoperative urinary free cortisol or late-night salivary cortisol remains elevated, or when clinical recurrence is suspected.

日本語の概要は準備中です。原文の説明を表示しています。

Work up a patient with confirmed hypercalcemia using the PTH-dependent vs. PTH-independent algorithm — order the right second-tier tests (PTHrP, 25(OH)D, 1,25(OH)2D, SPEP/UPEP, urinary calcium/creatinine clearance ratio, TSH) to reach a diagnosis. Trigger when a clinician asks "what's causing this hypercalcemia", "how to work up high calcium", "what tests to order for hypercalcemia", "PTH is normal what next", "differential diagnosis of hypercalcemia", or shares a confirmed hypercalcemia and asks for the workup.

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests pituitary-directed medical treatments (e.g., cabergoline, pasireotide) for patients with Cushing's disease who are not surgical candidates or have persistent disease after transsphenoidal surgery. Use when a CD patient cannot undergo surgery or has residual disease post-TSS; triggers include "not a surgical candidate", "persistent disease after TSS", "ongoing hypercortisolism despite prior surgery".

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating intravenous bisphosphonate or denosumab for adults with hypercalcemia of malignancy compared with no treatment. Use when a clinician asks about first‑line pharmacologic therapy for HCM or when deciding to start antiresorptive agents.

日本語の概要は準備中です。原文の説明を表示しています。